Should Everyone Take GLP-1s? (What Changed My Mind)
In a Nutshell
The speaker shifted from GLP-1 skepticism to strong support after reviewing evidence showing these drugs reduce obesity rates, improve brain, heart, liver, and joint health, and may directly lower Alzheimer's pathology beyond weight loss. Muscle loss is largely preventable with resistance training and high protein intake, while next-generation drugs like retatrutide and combination therapies with myostatin/activin blockers enable simultaneous fat loss and muscle gain. GLP-1s also curb addiction-like behaviors and the main risk is weight regain upon abrupt discontinuation without lifestyle changes.
These notes were generated by AI and may contain inaccuracies.
The speaker was initially skeptical of GLP-1s when they first became prominent for weight loss. This skepticism stemmed from historical patterns where medicine promotes miracle drugs only to later discover harms that were not initially apparent.
After deeper examination of the scientific literature on GLP-1s and newer generations such as retatrutide, the speaker's view shifted from believing the drugs are overhyped to potentially not being hyped enough. The speaker now sees the commonly discussed benefits as only the tip of the iceberg.
GLP-1s act on far more than weight alone, including the brain, heart, joints, liver, and even the tongue. Data suggest GLP-1s may directly reduce hallmarks of Alzheimer's disease completely independent of fat loss. When combining GLP-1s with other compounds, extreme body recomposition is possible, such as losing 50% body fat while gaining 6% lean mass.
The speaker aims to create a definitive GLP-1 guide addressing every major question. The video emphasizes highlights, common misunderstandings, and lesser-known information. A comprehensive guide is available at metabolism.com. The roadmap includes societal changes, common concerns, three generations of GLP-1 drugs, weight-independent effects, combination therapies, and a rapid-fire Q&A.
Semaglutide was approved for obesity in 2021. The US obesity rate fell from roughly 40% in 2022 to about 37% in 2025, representing 7.6 million fewer obese adults. GLP-1 usage among adults rose from 5.8% in February 2024 to 12.4% in 2025. Projections suggest a quarter of US adults may be on GLP-1s by 2028 and most people on stronger medications or combinations by the 2030s.
GLP-1s alter appetite and taste preference. The brain and tongue use GLP-1 to communicate, with the tongue secreting GLP-1 on nerves that connect to the brain. Nestle has launched food products specifically targeted at GLP-1 users.
Literature reports 25-40% of weight lost on GLP-1s at the population level is classified as lean mass. People losing weight through lifestyle alone may be more likely to resistance train and prioritize protein. This muscle loss appears preventable.
Nicholas N started at 321 lbs in November 2021. Using low-carb dieting and fasting, he lost 61 lbs but plateaued. After a diagnosis of hypogonadism, he was prescribed 200 mg per week of testosterone for replacement. He then used tirzepatide, consumed 200 g of protein daily, walked 10,000 steps per day, and resistance trained three to five times per week. Over a year and a half, he lost an additional 22 lbs, dropping from 36% to 19% body fat while gaining 25.6 lbs of lean mass.
A reasonable starting point is resistance training at least three times per week and consuming 0.7 to 1 g of high-quality protein per pound of lean mass while losing weight.
A study of identical twins found leg explosive power predicted better cognitive function and larger brain volume later in life. Muscles secrete myokines such as irisin and BDNF that fuel the brain. Muscles also support blood glucose control and insulin sensitivity, both important for brain health.
DEXA scans lump muscle with other soft tissues including the liver into a single lean mass category. They cannot distinguish metabolically active contractile muscle proteins from less functional intracellular substrates. A drop in lean mass on DEXA could reflect reduced muscle glycogen, water, or liver size rather than loss of functional muscle.
2026 research suggests GLP-1s may preferentially reduce liver mass and non-essential muscle components without affecting contractile machinery responsible for strength and function. Strength can be preserved despite reductions in measured lean mass. Some lean mass loss previously attributed to muscle may actually reflect shrinking livers and other non-critical components.
Rapid weight loss of any kind tends to reduce bone mass due to decreased skeletal load. GLP-1 receptors exist in bone cells. GLP-1 signaling stimulates osteoblasts and inhibits osteoclasts. In rats with insulin resistance, GLP-1 treatment improved bone quality and strength.
Reports link GLP-1s to non-arteritic anterior ischemic optic neuropathy. A 2026 systematic review found GLP-1 use was not significantly associated with this condition. Absolute risk is estimated at roughly half a percent in patients with diabetes over 5 years. Individuals with pre-existing retinal disease or diabetic eye disease should consult a physician before starting therapy.
Rodent studies showed GLP-1 drugs increased medullary thyroid carcinoma. GLP-1s carry warnings for individuals with personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Human evidence is more reassuring than headlines suggest.
Generation one drugs are GLP-1 receptor agonists such as Ozempic and Wegovy that primarily suppress appetite via the brain's hunger signal. Generation two drugs are dual agonists hitting both GLP-1 and GIP, influencing fat cell physiology and fuel partitioning in addition to appetite suppression. Generation three is retatrutide, which hits GLP-1, GIP, and glucagon. The glucagon component increases metabolic rate and energy expenditure.
First-generation drugs produce 10-15% body weight loss. Second-generation dual agonists produce around 20% body weight loss. Third-generation retatrutide produces about 24% body weight loss over a year, with slightly larger effects in women around 28%.
Retatrutide increases resting heart rate, raising questions about long-term cardiovascular stress over decades of use. In a one-month personal experiment at 1-2 mg, the speaker observed substantial drops in LDL and ApoB. The glucagon component lowers PCSK9, which in turn lowers LDL and ApoB.
Retatrutide may be muscle-sparing via glucagon-stimulated FGF-21 release. FGF-21 increases metabolic rate and could help preserve muscle during weight loss. Obesity is an FGF-21 resistant state, which may explain why published obesity trials have not shown muscle-sparing effects, while anecdotal reports from non-obese biohackers and bodybuilders suggest possible benefits.
Population data show lower dementia rates among GLP-1 users. Higher GLP-1 levels in the brain correlate with lower amyloid, a marker of Alzheimer's disease. GLP-1 inhibits BACE enzyme activity, biasing amyloid precursor protein toward a neuroprotective pathway rather than the amyloid-producing pathway. GLP-1s also improve brain insulin sensitivity, which can block GSK3-beta activation and reduce neurofibrillary tau tangles.
A 2026 study examined osteoarthritis. GLP-1s may directly influence cartilage-regenerating cells in joints. GLP-1 treatment has been associated with cartilage thickening in humans, providing benefits beyond weight loss alone.
The speaker, who maintains general pharmaceutical skepticism including concerns about statins, concludes that provided someone does not lose too much weight, the benefits of GLP-1s likely outweigh the risks for most people even beyond weight loss. The speaker has received no pharmaceutical industry funding.
The most interesting part of the GLP-1 story comes from the frontier. Combination treatments combine GLP-1s with compounds that support muscle growth. These combination therapies help people lose fat while building muscle, sometimes a lot of it. Evolutionarily, muscle is expensive. The body has the capacity to build large amounts of muscle, but under normal conditions that process is restrained by built-in biological breaks on muscle growth designed to conserve energy.
Some animals and humans have genetic mutations in which these breaks on muscle growth are broken, leading to low body fat and unbelievable musculature. Researchers are learning how to mimic this with small molecules in clinical trials. Two of the major breaks on muscle growth are called myostatin and activin A. Blocking these breaks unleashes muscle building potential and also fat loss.
In monkey studies, animals taking these breakers combined with GLP-1 drugs exhibited massive fat loss along with increases in lean mass. Total fat mass decreased by 50% while lean mass increased by 6%.
Early randomized controlled trial human data show similar signals. Over just eight weeks with one treatment, human participants gained roughly 3 kg (6.6 lb) of lean mass while losing 4 kg (8.8 lb) of fat mass after a single treatment. Muscle gain and fat loss occurred at the same time in a matter of weeks. The field is still early and there are unanswered safety questions, but if these approaches prove safe and scalable, they may fundamentally change the future of body recomposition medicine.
There are other compounds, lesser known but equally fascinating, that may produce similar biological effects without being injectables. One example is ATX304. It is an AMPK activator. AMPK is one of the master regulators of energy metabolism in the body. ATX304 helps pull fuel into muscles while simultaneously increasing fat burning and energy expenditure.
In one recent pre-clinical animal study, a 32-day treatment with ATX304 led to a 21% reduction in body weight, 100% of which came from fat. When ATX304 was combined with GLP-1s, there was a lot of fat mass loss with no reduction in lean mass. The speaker has some of this in their fridge and when they used it, it lowered their fasting blood sugar by 6 mg/dL. They have recommended ATX304 to two family members on GLP-1s and they now swear by it.
Within a few years, most people using GLP-1s will be incorporating adjunctive therapies alongside them. One example is ATX304, which in animal studies appears capable of preventing weight regain after stopping a GLP-1.
Orforglipron is a new oral non-peptide GLP-1. Weight loss appears to be broadly comparable to first generation GLP-1 injectables like Ozempic, with 11.2% body weight reduction over 72 weeks alongside improvements in metabolic markers. The real significance is the ability to take a pill rather than an injection. It is mostly an accessibility and preference thing.
If someone changes nothing about their lifestyle, starts a GLP-1, loses weight, and then abruptly stops it, they will typically regain the weight. This does not appear to represent permanent metabolic damage or a dependency created by the drug. It reflects a return to prior lifestyle patterns.
GLP-1s might function as a catalyst for lifestyle change. If they reduce food noise and allow someone to improve their lifestyle quality, make better dietary choices, establish healthier eating patterns, exercise more consistently, and improve their metabolic flexibility, then at some point someone might not need a GLP-1 or might be able to go down to a low maintenance dose. This is actually quite common. There is growing interest in adjunctive therapies that might help prevent rebound weight gain after GLP-1 discontinuation.
GLP-1 signaling reaches the brain, including regions involved in reward, craving, and addiction. There are genetic variants in GLP-1 receptors that have been associated with differences in alcohol self-administration and altered reward responses in the brain. GLP-1 drugs might influence alcohol use disorder, smoking, binge eating, and other compulsive behaviors. One of the most common reports from people taking GLP-1s is that the food noise got quieter, but it is not just food noise. It is alcohol noise, nicotine noise.
This does not mean losing pleasure from these things. Wanting and liking are very different circuits in the brain. GLP-1s primarily affect the wanting pathway, not necessarily the liking pathway.
GLP-1 drugs are supposed to slow stomach emptying. That is part of how they work. True gastroparesis refers to severe dysfunction of stomach emptying causing nausea and vomiting. Severe gastroparesis remains relatively uncommon on GLP-1s. The risk increases when doses are escalated aggressively, when on a very high dose, or when people overeat when gastric emptying is slowed per the intended mechanism.
Tips: start on a low dose, titrate up slowly, and do not binge eat. If taking a very high dose of a GLP-1 and eating a whole pizza out of habit, it will cause stomach troubles.
The reason for moving fairly quickly from being a skeptic to a relative fan is not because of conflicts of interest with pharma or a personal need for these drugs. It is because of time spent immersed in the scientific literature and seeing how these medications are affecting real people and loved ones. People have described it as fighting an uphill battle inside for decades, and now having a tool that is truly liberating, not a crutch, but an advantage in a world where modern environments are conspiring to keep people fat and sick. There is a meaningful amount of liberation in a world that is booby trapped by a toxic food environment. There is also real promise for what might happen under metabolic processes.
Keep Nick Norwitz in your library
Save the videos and channels worth coming back to, and find them again in one place.
